Precision radiotherapy may buy time for men with spreading prostate cancer
NCT ID NCT07691697
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study investigates whether precisely targeted radiotherapy can delay the need for stronger drugs in men with prostate cancer that has started to grow in a few new spots while on systemic therapy. Participants have metastatic hormone-sensitive or castration-resistant prostate cancer and develop up to five new or growing lesions detected by PSMA PET imaging. The treatment, called progression-directed radiotherapy, uses techniques like stereotactic body radiotherapy or brachytherapy to target only those active lesions. The goal is to see if this approach can postpone switching to a new line of systemic therapy and maintain control of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Progression-directed radiotherapy (stereotactic body radiotherapy, brachytherapy, or external beam radiotherapy)
- What this could lead to
- If successful, this approach could help men with prostate cancer delay switching to more aggressive systemic treatments, preserving quality of life.
- What could go wrong
- This is an observational registry, not a controlled trial, so results may be influenced by patient selection. Radiotherapy carries risks like fatigue, urinary or bowel irritation, and may not prevent further progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affidea Nu-Med Cancer Diagnostics and Therapy Center
RECRUITINGZamość, Lublin Voivodeship, 22-400, Poland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- Can a Two-Drug attack stall resistant prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
- Can a new daily pill slow advanced prostate cancer?
- Radiation plus hormone therapy may slow resistant prostate cancer
- Targeted radiation zaps prostate cancer cells in new trial